Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.47 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.47 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.47 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.47 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 7/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28184751 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL3249208 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL29978075 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL29977697 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL15047640 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL3249203 | 0.98 | NOD1 (0.56) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL3802336 | 0.97 | NOD1 (0.54) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL3802334 | 0.97 | NOD1 (0.54) | NOD1GPR84PPARGPPARDPPARA | |
| Stearic Acid SCHEMBL28060916 | 0.95 | GPR84 (0.55) | NOD1GPR84PPARGPPARDPPARA | |
| SCHEMBL24712636 | 0.92 | NOD1 (0.51) | NOD1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144046-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF ADMINISTRATION | METASTX LLC (US) | 2025-05-08 | — | — | US | disclosed |
| US-12156939-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118338903-A | Compositions and methods for enhancing WNT signaling for treatment of cancer | 麻省理工学院 | 2024-07-12 | — | — | CN | disclosed |
| CN-108473538-B | SSTR targeting conjugates and particles and formulations thereof | 塔弗达治疗有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113365653-A | Salt nanoparticles and compositions and methods of use thereof | 佐治亚大学研究基金会股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-2844737-A1 | HIGH YIELD TRANSIENT EXPRESSION IN MAMMALIAN CELLS USING UNIQUE PAIRING OF HIGH DENSITY GROWTH AND TRANSFECTION MEDIUM AND EXPRESSION ENHANCERS | Life Technologies Corporation (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013166339-A1 | HIGH YIELD TRANSIENT EXPRESSION IN MAMMALIAN CELLS USING UNIQUE PAIRING OF HIGH DENSITY GROWTH AND TRANSFECTION MEDIUM AND EXPRESSION ENHANCERS | Life Technologies Corporation (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20080089932-A1 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | MARINA BIOTECH, INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144046-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF ADMINISTRATION | PAK3, PAK1, PAK6 | PPARG 1720/4885HDAC11 1018/4885ESR1 3474/4885 |
| US-12156939-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | PPARG 1296/4885HDAC11 2644/4885ESR1 1996/4885 |
| US-20080089932-A1 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | LIPA, SGMS1, SGMS2 | PPARG 4048/4885HDAC11 2360/4885ESR1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.